Caliper, Monogram Removed from Nasdaq Biotech Index | GenomeWeb

NEW YORK (GenomeWeb News) – Caliper Life Sciences and Monogram Biosciences are among the firms that are being removed from the Nasdaq Biotechnology Index as of the open of the market on May 18.

The Nasdaq Biotech Index performs a semi-annual re-ranking of biotech firms that it considers for either adding or dropping from the Index. In this most recent re-ranking, it added four drug firms and dropped 16 firms.

The other research products firm that was dropped from the Index was Harvard Bioscience.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.